

Guideline for Antimicrobial Use in URINARY TRACT INFECTIONS at West Park Healthcare Centre

1. Empiric Antimicrobial Regimens

- The empiric regimens below are based on the 2024 WPHC antibiograms.
- Consider the patient's historical urine C&S results and recent antimicrobial regimens prior to selecting empiric treatment.
- Usual dosages are provided below; adjust in renal impairment.

Type of UTI	1 st Line Empiric Therapy	2 nd Line Empiric Therapy
UNCOMPLICATED CYSTITIS (NO systemic involvement)	Nitrofurantoin ^{a,b} monohydrate/macrocrystals capsule (MacroBID®) 100 mg PO q12h for 5 days If enteral tube: Nitrofurantoin tablet 50 mg ENT q6h for 5 days	Fosfomycin 3 g PO once
<u>MILD TO MODERATE</u> PYELONEPHRITIS or COMPLICATED UTI (clinically stable, systemic involvement)	Amoxicillin-clavulanic acid 875/125 mg PO q12h for 7 days If unable to tolerate oral: Ceftriaxone 1 g IV q24h for 7 days If suspected pathogen include: <u>ESBL/ampC organism:</u> - change to Ertapenem 1 g IV q24h for 7 days <u>Enterococcus faecalis</u> - ADD Ampicillin 1 g IV q6h	Sulfamethoxazole 800 mg/trimethoprim 160 mg (=1 DS tab or 2SS tabs) PO q12h for 7 days If sulfamethoxazole/trimethoprim cannot be used: - Ciprofloxacin 500 mg PO q12h for 7 days
<u>SEVERE</u> PYELONEPHRITIS or COMPLICATED UTI (high fever, sepsis/septic shock, clinically unstable)	Meropenem 1 g IV q8h AND Vancomycin 15 mg/kg IV q12h Duration: 7 days	If severe systemic/cutaneous adverse reaction to beta-lactams: Ciprofloxacin 400 mg IV q8h AND Vancomycin 15 mg/kg IV q12h If suspected pathogen include: <u>MDR gram-negative organisms</u> ADD Tobramycin 7 mg/kg IV q24h (while investigations are pending) Duration: 7 days

Notes:

^aNitrofurantoin is excreted in the urine into the bladder, and exerts its bactericidal activity **in the bladder**. Therefore, nitrofurantoin is **not** indicated in the treatment of **pyelonephritis or complicated UTI** due to poor renal tissue levels. Generally **avoid use if CrCl is less than 30 mL/min** due to insufficient excretion into the bladder at the site of infection.

^bDo **NOT** use **empirically** in men unless invasive disease (e.g., prostatitis, epididymitis) is ruled out.